Retrospective Analysis of Presentation, Treatment, and Outcomes of Multiple Myeloma at a Large Public Referral Hospital in Eldoret, Kenya

• Published in: JCO global oncology Vol. 7; no. 7; pp. 391 - 399
• Main Authors: Manyega, Kelvin M, Lotodo, Teresa C, Oduor, Mercy A, Namaemba, Diana F, Omondi, Austin A, Oyolo, Yvette L, Oguda, John, Loehrer, Patrick J, Vik, Terry A, Asirwa, Fredrick C
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health 01.03.2021; American Society of Clinical Oncology
• Subjects: Antineoplastic Combined Chemotherapy Protocols; Hospitals; Humans; Kenya - epidemiology; Male; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Multiple Myeloma - epidemiology; ORIGINAL REPORTS; Referral and Consultation; Retrospective Studies; Kenya
• ISSN: 2687-8941; 2687-8941
• DOI: 10.1200/GO.20.00573

Treatment patterns and survival outcomes of patients with multiple myeloma (MM) in Kenya have not been adequately characterized. The objectives of this study were to describe the clinical, laboratory, and imaging findings at diagnosis, to describe the treatment offered, and to determine the survival outcomes of patients with MM over an 11-year period. A retrospective chart review was carried out for all patients who were diagnosed and treated for MM at Moi Teaching and Referral Hospital from 2009 to 2019. The Kaplan-Meier method was used to estimate survival. Factors affecting survival were identified using univariate and multivariate analyses. A total of 221 patient charts were analyzed of which 124 belonged to male patients (56.1%). The median age at diagnosis was 61 years. Bone pain was the most common presenting complaint observed in 69.6% of 194 patients assessed. Out of 102 patients who received imaging studies, 60 (58.8%) had lytic lesions, 30 (29.4%) had fractures, whereas 30 (29.4%) had spinal cord compression. Anemia, renal failure, and hypercalcemia were observed in 87/187 (46.5%), 22/161 (13.7%), and 23/42 (54.8%) patients, respectively. Thalidomide and dexamethasone (65.2%); bortezomib, thalidomide, and dexamethasone (14.6%); and melphalan and prednisolone (11.9%) were the most prescribed initial chemotherapy regimens among 219 patients analyzed. Overall survival at 1 and 5 years was 70% and 21%, respectively; median overall survival was 29.0 months. In multivariate analysis, male sex (hazard ratio [HR] 1.9), baseline anemia (HR 1.8), and baseline renal failure (HR 3.2) were associated with significantly shorter survival. Survival outcomes were poor despite increased use of multiagent-based chemotherapy regimens. Greater access to available diagnostics and treatments is required to achieve rational treatment and increased survival.